MK-8325: A silyl proline-containing NS5A inhibitor with pan-genotype activity for treatment of HCV
- 1 June 2018
- journal article
- research article
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 28 (10) , 1954-1957
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Discovery of Ruzasvir (MK-8408): A Potent, Pan-Genotype HCV NS5A Inhibitor with Optimized Activity against Common Resistance-Associated PolymorphismsJournal of Medicinal Chemistry, 2016
- Kinetic Analyses Reveal Potent and Early Blockade of Hepatitis C Virus Assembly by NS5A InhibitorsGastroenterology, 2014
- Discovery of MK‐8742: An HCV NS5A Inhibitor with Broad Genotype ActivityChemMedChem, 2013
- New Merck and Vertex drugs raise standard of care in hepatitis CNature Biotechnology, 2011
- Multiple ascending dose study of BMS-790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1Hepatology, 2010
- Advances in nucleoside monophosphate prodrugs as anti-HCV agentsAntiviral Therapy, 2010
- Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effectNature, 2010
- HCV drug discovery aimed at viral eradicationJournal of Viral Hepatitis, 2010
- Ser2194 Is a Highly Conserved Major Phosphorylation Site of the Hepatitis C Virus Nonstructural Protein NS5AVirology, 2000
- Hepatitis C Virus NS5A Protein Is Phosphorylated by Casein Kinase IIBiochemical and Biophysical Research Communications, 1999